https://consumer.healthday.com/physician-s-briefing-nash-2661826022.html
0
0
6/30/23 at 10:29am
Organization
Healthday.com
Author
Elana Gotkine
43 words
0
Comments
FRIDAY, June 30, 2023 (HealthDay News) -- For patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and stage F2 or F3 fibrosis, treatment with pegozafermin leads to improvements in fibrosis, according to
You are the first to view
Create an account
or login to join the discussion